🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

9,250 results for “IO” Clear

  1. Aerobic Exercise

    The First People's Hospital of Lianyungang

    Primary Hypertension

    phase 3 other active

    1 trial

  2. Aficamten, Tablet placebo for aficamten 5mg tablet

    Cytokinetics (Ireland) Limited

    SYMPTOMATIC OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY

    phase 3 small molecule active

    1 trial

  3. Afinitor 10 mg tablets, Aromasin 25 mg coated tablets, Faslodex 250 mg solution for injection., Afinitor 5 mg tablets

    Pfizer Australia Pty Ltd

    Hormone receptor-positive, her2-negative advanced/metastatic breast cancer

    phase 3 small molecule active

    1 trial

  4. Afinitor 2.5 mg tablets, Afinitor 10 mg tablets

    The George Institute

    Children, adolescents and adults with newly diagnosed diffuse intrinsic pontine glioma and other diffuse midline gliomas H3K28M mutant or EZHIP positive

    phase 3 small molecule active

    1 trial

  5. Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Macular Degeneration

    phase 3 mab completed

    1 trial

  6. Aflibercept 8 mg

    Regeneron UK Limited

    Neovascular Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

  7. Aflibercept High Dose VEGF Trap-Eye (BAY86-5321)

    Regeneron UK Limited

    Neovascular Age-Related Macular Degeneration

    phase 3 small molecule completed

    1 trial

  8. Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)

    Regeneron UK Limited

    Retinal Vein Occlusion

    phase 3 mab completed

    1 trial

  9. Aflibercept, VEGF Trap-Eye(Eylea, BAY86-5321)_higher dose

    Regeneron UK Limited

    Macular Edema Secondary to Retinal Vein Occlusion

    phase 3 small molecule completed

    1 trial

  10. Agitated Saline SoC

    BRIGHT MINDS BIOSCIENCES INC.

    Right-To-Left Shunt

    phase 3 small molecule active

    1 trial

  11. Albendazole (400 mg) and/or Vitamin a

    United Therapeutics Europe Ltd

    Malnutrition

    phase 3 small molecule completed

    1 trial

  12. Albutein 50 g/l solución para perfusión.

    Instituto Grifols S.A.

    Subjects with cirrhosis with ACLF-1b, ACLF-2, or ACLF-3a detected either at admission or during hospitalization

    phase 3 small molecule active

    1 trial

  13. Albuterol Spiromax

    Teva Pharma GmbH

    Exercise-Induced Bronchoconstriction (EIB)

    phase 3 small molecule completed

    1 trial

  14. Aldurazyme

    BioMarin Pharmaceutical Australia Pty Ltd

    Mucopolysaccharidosis I

    phase 3 mab completed

    1 trial

  15. Alecensa 150 mg hard capsules, IMFINZI 50 mg/mL concentrate for solution for infusion.

    Hoffmann-La Roche

    Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  16. Alecensa 150 mg hard capsules, VINORELBINE, Gemcitabin-GRY 1000 mg Pulver zur Herstellung einer Infusionslösung, Carboplatin-GRY® 10 mg/ml Konzentrat zur Herstellung einer Infusionslösung, Carboplatin ACTAVIS 10 mg/ml concentrat pentru soluţie perfuzabilă, ALIMTA 500 mg powder for concentrate for solution for infusion, Cisplatin NeoCorp 1 mg/ml - Konzentrat zur Herstellung einer Infusionslösung, Alecensa 150 mg hard capsules

    Hoffmann-La Roche

    Completely resected, Stage Ib (tumors ≥ 4 cm) to Stage IIIa, Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)

    phase 3 small molecule active

    1 trial

  17. Alemtuzumab

    United Therapeutics Europe Ltd

    Kidney Transplantation

    phase 3 small molecule completed

    1 trial

  18. Alicaforsen

    IONIS PHARMACEUTICALS INC

    Crohn's Disease

    phase 3 small molecule completed

    2 trials

  19. Alirocumab

    Sanofi Pasteur

    Atherosclerotic Cardiovascular Disease

    phase 3 small molecule completed

    1 trial

  20. Alirocumab

    Regeneron UK Limited

    Atherosclerotic Cardiovascular Disease

    phase 3 small molecule completed

    1 trial

  21. Alogliptin and pioglitazone

    Takeda

    Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  22. Alogliptin and pioglitazone

    Takeda

    Type 2 Diabetes Mellitus

    phase 3 small molecule completed

    2 trials

  23. Ambrisentan Viatris 5 mg film-coated tablets, Placebo de AMBRISENTAN VIATRIS 5 mg - composition: cellulose microcristalline; lactose monohydraté; silice colloïdale anhydre; stéarate de magnésium (vegetable origin); opadry II 85G94065 PINK; eau purifiée, TADALAFIL

    Pari Pharma GmbH

    Pulmonary arterial hypertension

    phase 3 small molecule active

    1 trial

  24. Amikacin Inhalation Solution (BAY41-6551)

    Nektar Therapeutics UK Limited

    Pneumonia, Bacterial

    phase 3 small molecule completed

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources